Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Vedi grafici interattivi e bilanci completi → Modello di valutazione (DCF) →
| Conto economico | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Entrate totali | $831M | $761M | $675M | $482M | $402M | $366M | $354M | $306M | $251M | $159M | $81M | $50M | $27M | $10M | $3M | $0M | — | $0M | $0M | $0M | $0M |
| Utile lordo | $817M | $748M | $664M | $476M | $396M | $361M | $348M | $301M | $246M | $156M | $79M | $49M | $26M | $10M | $3M | $0M | — | $0M | $0M | $0M | $0M |
| Margine lordo% | 98.3% | 98.3% | 98.4% | 98.7% | 98.7% | 98.6% | 98.4% | 98.2% | 97.9% | 97.8% | 97.5% | 97.3% | 96.7% | 98.6% | 97.2% | — | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Risultato Operativo (EBIT) | $6M | $45M | $137M | $107M | $113M | $124M | $128M | $112M | $89M | $53M | $10M | ($3M) | ($28M) | ($41M) | ($36M) | ($32M) | ($27M) | ($20M) | ($20M) | ($12M) | ($26M) |
| Margine operativo % | 0.8% | 5.9% | 20.3% | 22.2% | 28.0% | 34.0% | 36.2% | 36.4% | 35.6% | 33.2% | 12.5% | -6.9% | -104.0% | -400.7% | -1096.8% | — | — | -69827.6% | -9420.6% | -2540.5% | -8701.4% |
| Reddito netto | $55M | $100M | $140M | $106M | $101M | $113M | $106M | $94M | $75M | $129M | $8M | ($6M) | ($31M) | ($46M) | ($38M) | ($32M) | ($26M) | ($20M) | ($20M) | ($12M) | ($25M) |
| Margine netto% | 6.6% | 13.1% | 20.7% | 22.0% | 25.2% | 30.7% | 30.0% | 30.7% | 30.0% | 81.1% | 10.0% | -12.7% | -118.2% | -444.2% | -1150.5% | — | — | -69537.9% | -9598.6% | -2401.0% | -8460.2% |
| EBITDA | $23M | $68M | $163M | $126M | $116M | $128M | $130M | $114M | $90M | $53M | $10M | ($3M) | ($27M) | ($41M) | ($36M) | ($32M) | ($26M) | ($20M) | ($20M) | ($12M) | ($26M) |
| Utile per azione (EPS) | $0.42 | $0.83 | $1.23 | $0.95 | $0.87 | $0.89 | $0.85 | $0.77 | $0.60 | $1.04 | $0.07 | $-0.06 | $-0.31 | $-0.46 | $-0.41 | $-0.39 | $-0.38 | $-0.38 | $-0.43 | $-0.34 | $-1.09 |
| Azioni in circolazione (M) | 118M | 120M | 113M | 112M | 116M | 126M | 124M | 123M | 127M | 125M | 116M | 107M | 101M | 100M | 93M | 83M | 68M | 52M | 47M | 34M | 23M |
Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.
Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di CORT. /companies/us/CORT
Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.
About TickerBase · Data methodology & sources · Privacy · Terms